- Home
- MTA vs PSNL Comparison
MTA vs PSNL Comparison
Compare MTA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTA | PSNL |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.4M | 729.1M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MTA | PSNL |
|---|---|---|
| Price | $6.80 | $6.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.00 | ★ $12.20 |
| AVG Volume (30 Days) | 427.8K | ★ 1.5M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | $81.63 | $15.34 |
| Revenue Next Year | $62.44 | $41.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.83 | $3.63 |
| 52 Week High | $9.25 | $11.50 |
Technical Indicators
Market Signals| Indicator | MTA | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 38.92 |
| Support Level | $6.48 | $5.81 |
| Resistance Level | $7.21 | $6.99 |
| Average True Range (ATR) | 0.32 | 0.43 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 45.39 | 26.41 |
Price Performance
Historical ComparisonAbout MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.